Guidelines update, v40.2

Version 40.2 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of three new studies on disease-modifying treatments. In addition, the treatment ‘REGN-COV2’ has been renamed to ‘casirivimab plus imdevimab (REGEN-COV)’:

• Casirivimab plus imdevimab (REGEN-COV) – two new studies comparing casirivimab plus imdevimab to usual care (Horby et al. doi: 10.1101/2021.06.15.21258542) and placebo (O’Brien et al. doi: 10.1101/2021.06.14.21258569);
• Tofacitinib NEW – one new study comparing tofacitinib to placebo (Guimarães et al. NEJM doi: 10.1056/NEJMoa2101643)

These studies are currently under review and will be incorporated in a future version of the guidelines.

Ends.